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Determining the association between adipokine expression in
multiple tissues and phenotypic features of non-alcoholic fatty
liver disease in obesity
MGM Wolfs1,11, N Gruben1,11, SS Rensen2, FJ Verdam2, JW Greve2, A Driessen3,4, C Wijmenga5, WA Buurman6, L Franke5,7, L Scheja8,
DPY Koonen1, R Shiri-Sverdlov9, TW van Haeften1,10, MH Hofker1,11 and J Fu5,11
OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is an obesity-associated disease, and in obesity adipokines are believed to
be involved in the development of NAFLD. However, it is still not clear whether adipokines in the liver and/or adipose tissues can be
related to the development of speciﬁc characteristics of NAFLD, such as steatosis and inﬂammation. We aimed to address this
question by simultaneously examining the adipokine expression in three tissue types in obese individuals.
METHODS: We enrolled 93 severely obese individuals with NAFLD, varying from simple steatosis to severe non-alcoholic
steatohepatitis. Their expression of 48 adipokines in the liver, visceral and subcutaneous adipose tissue (SAT) was correlated to their
phenotypic features of NAFLD. We further determined whether the correlations were tissue speciﬁc and/or independent of
covariates, including age, sex, obesity, insulin resistance and type 2 diabetes (T2D).
RESULTS: The expression of adipokines showed a liver- and adipose tissue-speciﬁc pattern. We identiﬁed that the expression of
leptin, angiopoietin 2 (ANGPT2) and chemerin in visceral adipose tissue (VAT) was associated with different NAFLD features,
including steatosis, ballooning, portal and lobular inﬂammation. In addition, the expression of tumor necrosis factor (TNF),
plasminogen activator inhibitor type 1 (PAI-1), insulin-like growth factor 1 (somatomedin C) (IGF1) and chemokine (C-X-C motif)
ligand 10 (CXCL10) in the liver tissue and the expression of interleukin 1 receptor antagonist (IL1RN) in both the liver and SAT were
associated with NAFLD features. The correlations between ANGPT2 and CXCL10, and NAFLD features were dependent on insulin
resistance and T2D, but for the other genes the correlation with at least one NAFLD feature remained signiﬁcant after correcting for
the covariates.
CONCLUSIONS: Our results suggest that in obese individuals, VAT-derived leptin and chemerin, and hepatic expression of TNF, IGF1,
IL1RN and PAI-1 are involved in the development of NAFLD features. Further, functional studies are warranted to establish a causal
relationship.
Nutrition & Diabetes (2015) 5, e146; doi:10.1038/nutd.2014.43; published online 9 February 2015
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is an obesity-associated
disease ranging from relatively benign hepatic steatosis
to non-alcoholic steatohepatitis (NASH), severe cirrhosis
and ﬁbrosis. NASH is characterized by steatosis, hepatic
inﬂammation and cytological ballooning.1 With the increasing
prevalence and severity of obesity and type 2 diabetes (T2D),
more patients with NASH will progress to potentially fatal,
end-stage liver disease. Speciﬁcally, it was shown that almost
half of the patients with NASH have advanced ﬁbrosis,2 and
that 10–25% of the NASH patients will progress to show severe
liver pathology such as liver cirrhosis and/or hepatocellular
carcinoma,3–6 which are associated with high morbidity and
mortality.3,5,7
As NAFLD is strongly associated with obesity and the metabolic
syndrome,8 one hypothesis is that the altered release of
adipokines (signaling molecules from the adipose tissue) that
occurs in the metabolic syndrome may be involved in the
development of NAFLD.9 These adipokines can enter the blood-
stream and reach the liver.10 Adipokines derived from visceral
adipose tissue (VAT) may be speciﬁcally important, as visceral
adiposity is related to obesity-associated co-morbidities such as
NAFLD.11 Previous studies have identiﬁed an association between
elevated plasma levels of the adipokine leptin and NASH in
humans.12 However, as many adipokines are also expressed in the
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liver and other organs,13,14 a link between peripheral plasma levels
and NASH does not provide evidence that the expression of these
adipokines in VAT is associated with NASH.
To date, 48 adipokines have been deﬁned in the literature.15–18
However, no systematic analyses have been reported on their role
in the development of speciﬁc characteristics of NAFLD, such as
steatosis and inﬂammation. In this study, we correlated the
expression of 48 adipokines in human hepatic, visceral and
subcutaneous adipose tissue (SAT) to speciﬁc features of NAFLD in
severely obese individuals. We aimed to identify whether




Between 2006 and 2009, 93 severely obese individuals with a body mass
index (BMI) ranging from 30 to 74 kgm− 2 underwent elective bariatric
surgery at the Department of General Surgery, Maastricht University
Medical Centre (Maastricht, The Netherlands). Subjects with acute or
chronic inﬂammatory diseases, degenerative diseases and those reporting
an alcohol intake exceeding 10 g per day or using anti-inﬂammatory drugs
were excluded. This study was approved by the Medical Ethics Board of
Maastricht University Medical Centre and informed written consent was
obtained from each individual.
Histological assessment of liver pathology
Wedge liver biopsies were ﬁxed in formalin and embedded in parafﬁn for
histological staining. They were analyzed by an experienced pathologist
who was blinded to the clinical and biochemical parameters. Each
individual was scored for seven different histological parameters of liver
pathology: steatosis, ﬁbrosis, inﬂammation (lobular inﬂammation, large
lipogranulomas, portal inﬂammation), liver cell injury (ballooning) and
glycogenated nuclei according to the scoring system described by Kleiner
et al.19
Tissue sampling, histology preparation and mRNA isolation
Tissue sampling and RNA isolation have been described before.20 In brief,
RNA was isolated from VAT, SAT and liver tissue obtained during bariatric
surgery with the Qiagen Lipid Tissue Mini Kit (Qiagen, Hilden, Germany,
74804). The Agilent Bioanalyzer (Agilent Technologies, Waldbronn,
Germany, 5067–1521) was used to assess RNA quality and concentration.
mRNA proﬁling and normalization
mRNA pre-hybridization processing and hybridization were performed as
described before.20,21 Anti-sense RNA synthesis, ampliﬁcation and puriﬁca-
tion were performed according to the manufacturer’s protocol, using the
Ambion Illumina TotalPrep Ampliﬁcation Kit (Applied Biosystems/Ambion,
Austin, TX, USA). Complementary RNA was hybridized to microarrays
containing 48 755 probes, which targeted 37 776 different genes (Illumina
HumanHT12 BeadChips, Illumina, San Diego, CA, USA). These microarrays
were scanned on the Illumina BeadArray Reader. After quality control and
normalization,20 a total of 82 liver samples, 90 SAT samples and 84 VAT
samples were retained for further analysis. The expression data are freely
available in the Gene Expression Omnibus (GSE22070).
mRNA analysis of adipokines
To gain insight into the tissue-speciﬁc expression of adipokines and their
roles in NAFLD, we focused on 69 probes that targeted 48 adipokines,
which have been well deﬁned in the literature.15–18 If multiple probes were
annotated for the same gene, we took the average intensity of these
probes per gene. All analyses were done using R (version 2.15.1)
(R Foundation for Statistical Computing, Vienna, Austria). The heatmap
and hierarchical clustering of adipokine expression in these three tissue
samples was plotted using R package Gplots (version 2.11.0). The distance
was calculated using the Euclidean distance, and the samples and genes
were clustered using the ‘complete’ method. To identify potentially
confounding factors, we calculated Spearman correlation coefﬁcients
between phenotypic features of NAFLD and sex, age, BMI, waist-to-hip
ratio (WHR), the diagnosis of T2D and the homeostasis model assessment
of insulin resistance (HOMA-IR). In addition, the inter-correlation among
NAFLD features and the inter-tissue correlation of adipokine expression
levels were computed using the same method (see Supplementary
Statistical Notes 1).
To determine how adipokines are involved in NAFLD, we ﬁrst computed
Spearman correlations between liver histology scores and the expression
levels of adipokines from each tissue type. The signiﬁcance of correlation
was determined as 7.03 × 10− 4, which corresponds to a false discovery rate
of 0.05, using 1000× permutations (see Supplementary Statistical Notes 2).
A partial correlation analysis was performed to correct for inter-tissue
correlations of adipokine expression levels and to determine the most
relevant tissue type (R package ppcor, version 1.0). To regress out the
effect of confounding factors (age, sex, BMI, WHR, T2D and HOMA-IR), we
performed conditional regression analysis (see Supplementary Statistical
Notes 3).
Plasma measurement of chemerin and ANGPT2
For determination of plasma adipokine levels, venous blood samples were
collected in EDTA tubes after an 8-h fasting period. Plasma was used to
measure chemerin and angiopoietin 2 (ANGPT2) levels using commercially
available enzyme-linked immunosorbent assay (R&D Systems, Abingdon,
UK). A Spearman correlation analysis was used to test the correlation
between plasma levels, gene expression and different NAFLD features.
RESULTS
Severely obese individuals show varying degrees of NAFLD
Plasma parameters and clinical traits of all the subjects are shown
in Supplementary Table 1. We scored 7 histological characteristics
of NAFLD in 93 severely obese individuals, following Kleiner et al.’s
method.19 Of these individuals, 25 showed no signs of NAFLD,
while 8 showed simple steatosis without inﬂammation. The other
60 individuals had steatosis accompanied by varying degrees of
inﬂammation (Table 1).
NAFLD characteristics correlated with other phenotypes and
adipokine expression shows inter-tissue correlations
No strong associations between NAFLD features and sex or age
were observed (Figure 1a). In line with clinical observations,8 the
NAFLD features steatosis, ﬁbrosis, ballooning and inﬂammation
were correlated with BMI, WHR, T2D and HOMA-IR (Figure 1a).
Many NAFLD features also showed signiﬁcant inter-correlations.
For example, in accordance with its central role in NAFLD, steatosis
was correlated with all other NAFLD features scored (Figure 1b).
Hierarchical clustering of samples based on the genome-wide
gene expression in the liver, SAT and VAT (Supplementary Figure 1)
showed that sample clusters did not correspond to any cofactors or
NAFLD features. Thus, general differences in gene expression in






0 1 2 3
Steatosis (0–3) 93 25 26 29 13
Fibrosis (0–3) 91 62 15 11 3
Lobular inﬂammation (0–3) 88 36 35 12 5
Large lipogranulomas (0–1) 92 70 22 — —
Portal inﬂammation (0–1) 93 72 21 — —
Ballooning (0–2) 92 49 39 4 —
Glycogenated nuclei (0–1) 90 74 16 — —
The data shown are the total number of individuals scored for each marker
and the number of individuals with different grades for the seven features
of non-alcoholic fatty liver disease, as described in (ref. 19).
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Figure 1. Correlations of features of NAFLD. (a) The correlation between the NAFLD features and sex, age, BMI, WHR, T2D and HOMA-IR.
(b) The inter-correlation among the NAFLD features. The correlations were computed with Spearman correlation and conﬁdence ellipses serve
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Figure 2. The expression of adipokines in liver tissue, subcutaneous and VAT. (a) The heatmap diagram shows the differential gene expression
in joints from the three tissue types. The tissue samples (top row: red, liver samples; green, VAT samples; blue, SAT samples) and genes
(left side) are clustered hierarchically. Each column represents a tissue sample and each row represents the expression of a single gene
(green, low expression; red, high expression). (b) Venn diagram showing correlation of gene expression between tissues at false discovery
rate= 0.05.
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obese individuals cannot explain a possible association between
adipokine expression and NAFLD features (Supplementary Figure 1).
Most of the adipokines showed tissue-dependent expression,
which allowed us to classify tissue samples based on their
expression proﬁle (Figure 2a). Of the 48 adipokines tested, 26 did
not show inter-tissue correlation, but 22 adipokines showed
expression levels that were correlated between two or three
tissues (Figure 2b). Twenty adipokines showed an inter-tissue
correlation between VAT and SAT, and six adipokines showed an
inter-tissue correlation between SAT and hepatic tissue. The
expression of 10 adipokines was correlated between VAT and
hepatic tissue (Figure 2b).
The expression of eight adipokines was associated with NAFLD
features
We observed that the expression levels of eight adipokines
(angiopoietin 2 (ANGPT2), leptin, chemerin, tumor necrosis factor
(TNF), interleukin (IL)-1 receptor antagonist (IL1RN), chemokine
(C-X-C motif) ligand 10 (CXCL10), insulin-like growth factor 1
(somatomedin C) (IGF1) and plasminogen activator inhibitor
type 1 (PAI-1)) in one or more tissue types correlated with
steatosis, ballooning, lobular inﬂammation, portal inﬂammation
and/or ﬁbrosis at Po7.0×10−4 (false discovery rate o0.05) (Table 2
and Figure 3). Large lipogranulomas and glycogenated nuclei did
not correlate with adipokine expression levels. As the expression
levels of many adipokines showed inter-tissue correlations
(Figure 2b), we performed a partial correlation analysis to correct
for the impact of the other tissues. This allowed us to identify the
most relevant tissue type associated to NAFLD. The expression of
chemerin in both SAT and VAT was negatively correlated with
lobular inﬂammation. Taking into account the co-expression of
chemerin in both adipose tissues (Figure 2b), the partial correlation
analysis showed that only chemerin expression in VAT was
associated with lobular inﬂammation (Table 2). In this way, we
identiﬁed three adipokines (ANGPT2, leptin and chemerin) whose
expression in VAT was associated to lobular inﬂammation,
ballooning and/or steatosis. In addition, the expression of TNF,
IL1RN, CXCL10, IGF1 and PAI-1 in the liver, and the expression of
IL1RN in SAT, were correlated to NAFLD features (Table 2).
Of the individuals in our cohort, 67 out of 93 (72%) were women
with age ranging between 17 and 65 years, including 13 women
aged over 50 years, some of whom might be post menopausal.
The menopausal status may have an effect on cytokine expression
and NAFLD development, but we had no information on their
menopausal status. We therefore ﬁrst investigated the correlation
between adipokines and NAFLD features by correcting for age and
gender. After correcting for this, all the detected correlations
remained signiﬁcant (Table 2). Next, we conﬁned the analysis to 54
women under 50 years old and observed the same effects
(Supplementary Table 2). These results suggest that the
Table 2. The adipokines that were correlated with features of NAFLD
Gene Feature Tissue Not corrected Tissue corrected Age, sex corrected Age, sex, obesity
corrected
Age, sex, obesity,
T2D and IR corrected
Correlation Correlation Correlation Correlation Correlation
P-value P-value P-value P-value P-value
ANGPT2 Lobular inﬂam. VAT 0.42 0.36 0.45 0.40 0.24
P= 1.1 × 10− 4 P= 2.1 × 10− 3 P= 3.1 × 10− 5 P= 0.0027 P= 0.11
Leptin Lobular inﬂam. VAT 0.39 0.34 0.406 0.33 0.28
P= 4.0 × 10− 4 P= 3.3 × 10− 3 P= 2.1 × 10− 4 P= 0.016 P= 0.05
Steatosis VAT 0.41 0.40 0.454 0.038 −0.031
P= 9.4 × 10− 5 P= 2.5 × 10− 4 P= 1.46× 10− 5 P=0.781 P= 0.83
Chemerin Lobular inﬂam. VAT − 0.51 − 0.41 − 0.552 − 0.54 − 0.49
P= 1.5 × 10− 6 P= 3.0 × 10− 4 P= 1.33× 10− 7 P= 2.9 × 10− 5 P= 5.1 × 10− 4
Lobular inﬂam. SAT − 0.37 −0.17 − 0.347 − 0.32 −0.22
P= 5.6 × 10− 4 P=0.17 P= 0.00114 P= 0.016 P= 0.13
Portal inﬂam. VAT − 0.37 − 0.31 − 0.375 − 0.34 − 0.28
P= 5.9 × 10− 4 P= 7.2 × 10− 3 P= 4.5 × 10− 3 P= 0.0092 P= 0.05
Steatosis VAT − 0.39 − 0.24 − 0.39 − 0.32 − 0.31
P= 2.9 × 10− 4 P= 0.037 P= 2.1 × 10− 3 P= 0.015 P= 0.03
IL1RN Lobular inﬂam. Liver 0.46 0.38 0.44 0.45 0.40
P= 2.2 × 10− 5 P= 9.1 × 10− 4 P= 4.9 × 10− 5 P= 4.5 × 10− 4 P= 0.0038
Ballooning SAT 0.39 0.41 0.38 0.42 0.32
P= 1.4 × 10− 4 P= 2.4 × 10− 3 P= 2.6 × 10− 4 P= 9.2 × 10− 4 P= 0.019
CXCL10 Steatosis Liver 0.38 0.35 0.38 0.27 0.25
P= 4.9 × 10− 4 P= 1.7 × 10− 3 P= 5.2 × 10− 4 P= 0.036 P=0.069
Fibrosis Liver 0.40 0.33 0.40 0.19 0.21
P= 2.9 × 10− 4 P= 3.5 × 10− 3 P= 2.0 × 10− 4 P=0.16 P=0.145
IGF1 Steatosis Liver − 0.41 − 0.37 − 0.43 − 0.32 − 0.29
P= 1.5 × 10− 4 P= 9.8 × 10− 4 P= 4.8 × 10− 5 P= 0.012 P= 0.037
PAI-1 Lobular inﬂam. Liver 0.55 0.42 0.52 0.49 0.43
P= 2.5 × 10− 7 P= 2.0 × 10− 4 P= 1.1 × 10− 6 P= 9.4 × 10− 5 P= 0.0018
Portal inﬂam. Liver 0.37 0.25 0.38 0.46 0.39
P= 6.6 × 10− 4 P= 0.028 P= 4.8 × 10− 4 P= 1.7 × 10− 4 P= 0.0034
TNF Lobular inﬂam. Liver 0.38 0.29 0.34 0.27 0.38
P= 7.0 × 10− 4 P= 0.014 P= 0.0027 P= 0.044 P= 0.0063
Abbreviations: BMI, body mass index; FDR, false discovery rate; HOMA-IR, homeostasis model assessment of insulin resistance; Inﬂam., inﬂammation; NAFLD,
non-alcoholic fatty liver disease; SAT, subcutaneous adipose tissue; T2D, type 2 diabetes; VAT, visceral adipose tissue; WHR, waist-to-hip ratio. The table shows
all the adipokines that were correlated with liver histology (FDRo0.05) and the correlation adjusted for tissue type and covariates, including age, sex, BMI,
WHR, HOMA-IR and T2D. Bold values indicate the correlations that were not signiﬁcant at P⩽ 0.05 after correction.
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correlations detected between adipokines and NAFLD develop-
ment are independent of age, sex and menopausal status.
NAFLD is an obesity-related disease and shows high comorbid-
ity with other obesity-related complications, such as insulin
resistance and T2D. Our data also showed that BMI, WHR, T2D
and HOMA-IR were correlated with several NAFLD features
(Figure 1a). We therefore examined whether the correlation
between adipokine expression and NAFLD features was depen-
dent on these confounders. After step-wise correction for the
effect of age, sex, obesity and diabetes parameters, the correla-
tions between leptin expression in VAT and steatosis were no
longer signiﬁcant. In addition, the correlation for CXCL10 expres-
sion in liver and ANGPT2 expression in VAT disappeared (Table 2),
which indicates that these correlations were largely dependent on
the obesity and other obesity-related disorders. Nevertheless, the
other correlations were still signiﬁcant at Po0.05 after this
correction (Figure 3 and Table 2).
Peripheral plasma chemerin and ANGPT2 levels do not correlate
with NAFLD features
Adipokines derived from VAT may be important in the etiology of
NAFLD, as visceral adiposity is mainly related to obesity-associated
NAFLD.11 As adipokines expressed in adipose tissue are expected
to have endocrine effects on the liver through secretion in the
bloodstream, we measured plasma chemerin and ANGPT2 levels
(Supplementary Table 1). However, we found no evidence that
plasma chemerin and ANGPT2 levels were associated to NAFLD
features (Table 3). Moreover, plasma chemerin levels did not
correlate with chemerin expression in any of the three tissues. Only
hepatic expression of ANGPT2 correlated with plasma ANGPT2
levels (Table 3).
DISCUSSION
We have simultaneously assessed the expression of 48 adipokines
in the liver, VAT and SAT, to identify which adipokines in which
tissues were associated with speciﬁc features of NAFLD. We
observed that the hepatic expression of ﬁve genes, including TNF,
IGF1, IL1RN, PAI-1 and CXCL10, was correlated with NAFLD features.
These correlations were independent of obesity and T2D, except
for CXCL10. The central role of these adipokines in the progression
of NAFLD is supported by many publications. TNF activates c-Jun
NH2-terminal kinase and inhibitor of κB-kinase-β, thus resulting in
increased production of additional inﬂammatory cytokines.22 In
addition, enhanced TNF signaling was reported to aggravate
hepatic inﬂammation and ﬁbrosis in mice.23 These ﬁndings are in
line with the positive association we found between TNF
expression in the liver and lobular inﬂammation. IL1RN is an
antagonist of the IL-1 receptor and reduces the inﬂammation-
related activities of IL-1A and 1B.24 IL1RN serum levels as well as
liver mRNA expression have been correlated to features of the
metabolic syndrome, including NASH.25,26 The latter ﬁndings are
conﬁrmed by our study. CXCL10 stimulates monocyte and T-cell
migration.27 Hepatic CXCL10 mRNA expression is associated with
the presence of necro-inﬂammatory foci in the liver in mice on a
methionine- and choline-deﬁcient diet.28 Our data now add that
hepatic CXCL10 expression is also associated with the develop-
ment of ﬁbrosis and steatosis in human NASH. However, we
showed that this correlation was dependent on morbid obesity
and related disorders. Thus, its role in the development of NAFLD
needs further investigation in a larger cohort of NAFLD patients,
with and without other obesity disorders. IGF1 has a similar
function to insulin. IGF1 plasma levels are decreased in individuals
with hepatic steatosis29 and hepatic mRNA expression of IGF1 is
negatively correlated to ﬁbrosis.30 In line with this, we observed a
negative correlation between IGF1 expression in the liver and
steatosis. PAI-1 is known to be an inhibitor of ﬁbrinolysis.31
Hepatic gene expression and plasma PAI-1 levels are higher in
individuals with NAFLD and NASH compared with healthy
controls, and increase in parallel with the severity of NAFLD
features, including lobular inﬂammation.32 This was conﬁrmed by






















Figure 3. The tissue-speciﬁc correlation between adipokine expres-
sion and liver histology. Each gene node indicates the expression of
a gene in a certain tissue type and each line indicates a signiﬁcant
correlation with liver histology after correction for expression in
other tissue types. The arrowhead indicates a positive correlation
and the bar head a negative correlation (Po0.05). The dashed line
indicates a correlation that is dependent on covariates, including
age, sex, BMI, WHR, T2D and/or HOMA-IR.
Table 3. Correlation between plasma adipokine levels and tissue
expression levels or features of non-alcoholic fatty liver disease
ANGPT2 Chemerin
Correlation P-value Correlation P-value
Expression levels
Liver 0.313* 0.035 0.171 0.255
SAT 0.225 0.128 0.098 0.511
VAT 0.198 0.198 0.066 0.671
Features
Steatosis 0.098 0.501 − 0.072 0.622
Fibrosis 0.201 0.170 − 0.275 0.058
Lobular inﬂammation 0.028 0.852 − 0.118 0.431
Large lipogranulomas − 0.005 0.973 − 0.174 0.236
Portal inﬂammation 0.148 0.309 0.152 0.296
Ballooning 0.239 0.102 − 0.184 0.209
Glycogenated nuclei − 0.052 0.730 − 0.099 0.509
Abbreviations: ANGPT2, angiopoietin 2; NAFLD, non-alcoholic fatty liver
disease; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
Correlation coefﬁcients of plasma adipokine levels and tissue expression
levels or features of NAFLD are shown, with their respective P-value. The
signiﬁcance threshold for these correlation coefﬁcients was 0.28
(*Po0.05).
Adipokine expression in fatty liver disease
MGM Wolfs et al
5
Nutrition & Diabetes (2015) 1 – 7
expression and lobular inﬂammation. Inhibition of ﬁbrinolysis by
PAI-1 may cause lobular inﬂammation due to tissue damage
induced by increased ﬁbrin deposition.
Interestingly, our study showed that the expression levels of
three genes in VAT (leptin, chemerin and ANGPT2) were associated
with NAFLD features. This reinforces the detrimental role of VAT in
liver diseases.11 Leptin regulates food intake and energy
expenditure, and is elevated in obesity.33 However, the role of
leptin in the development of NASH has been controversial. Several
studies have shown that plasma leptin levels are elevated in
patients with NASH34 and are correlated with steatosis,12 whereas
others did not ﬁnd any association.35,36 The positive association
we found between leptin expression in VAT and lobular
inﬂammation after adjusting for age, gender, BMI and WHR,
suggests that leptin contributes to the development of hepatic
inﬂammation in NAFLD. This is in line with the previous ﬁndings
that leptin is also important in regulating immune function.37 We
observed that the ANGPT2 expression in VAT is related to lobular
inﬂammation in NASH, although we also showed that this
correlation was dependent on the presence of insulin resistance
and/or T2D. This is in line with previous research that showed
elevated ANPGT2 plasma levels in obese and T2D patients.38–40
The most striking observation of our study was that chemerin
expression in VAT was negatively correlated to steatosis, lobular
inﬂammation and portal inﬂammation independent of obesity,
T2D and HOMA-IR. The literature reports conﬂicting evidence on
the role of chemerin in inﬂammation and NAFLD. Mice lacking the
chemerin receptor, chemokine-like receptor 1, were resistant to
central nervous system inﬂammation,41 but more susceptible to
inﬂammation in models of inﬂammatory pulmonary disease.42,43
In addition, these mice were reported to have reduced hepatic
steatosis and hepatic inﬂammation in one study,44 whereas this
was not affected in another study.45 Our study now suggests that
increased chemerin expression in VAT may reduce hepatic
inﬂammation. We further investigated whether this association
can be explained by endocrine effects, as adipokines are secreted
into the bloodstream from adipose tissue. However, in contrast to
earlier studies,46,47 chemerin plasma levels did not correlate with
NAFLD features in our study nor with chemerin expression levels
in the three tissues under study (Table 3). Further analyses are
needed to investigate the underlying mechanisms behind the
negative correlation between chemerin expression in VAT and
hepatic inﬂammation.
In conclusion, our results suggest that leptin, chemerin, ANGPT2,
TNF, CXCL10, IGF1, IL1RN and PAI-1 could have a role in the
development of speciﬁc features of the NAFLD phenotype. Most
of the observed effects were independent of age, sex, obesity,
insulin resistance and T2D. As it is not known why some patients
with fatty liver progress towards hepatic inﬂammation while
others do not, it is tempting to suggest that adipokines have a role
in this process. Further functional studies with gene knockout
animal models and tissue culture experiments may provide more
information on the association we have discovered between
adipokines and speciﬁc features of the NAFLD phenotype.
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